1
|
Shiga T, Kono M, Murakami D, Sakatani H, Ogura K, Hotomi M. Traditional Japanese herbal medicine Hochuekkito protects development of sepsis after nasal colonization in mice. J Infect Chemother 2024:S1341-321X(24)00123-5. [PMID: 38677389 DOI: 10.1016/j.jiac.2024.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 04/01/2024] [Accepted: 04/24/2024] [Indexed: 04/29/2024]
Abstract
INTRODUCTION Streptococcus pneumoniae, a commensal in the nasopharynx, can cause invasive pneumococcal diseases (IPDs). To prevent the aggravation of IPDs, it is important to enhance host immune defense against S. pneumoniae. Hochuekkito (HET) is expected to have an immunostimulatory effect against infections. METHODS HET was administrated by gavage to adult BALB/cA mice before and after intranasal inoculation of S. pneumoniae. We evaluated the effect of HET on pneumococcal nasal colonization and subsequent development of lethal pneumococcal infections. RESULTS No effect on nasal colonization was observed, but HET significantly reduced bacterial count in the blood, decreased the incidence of bacteremia, and improved survival. HET also reduced nasal tissue damage 3 days after intranasal infection. Neutrophils from HET-treated mice showed significantly higher bactericidal activity against S. pneumoniae in the presence of the serum from the HET group compared with from the control group. CONCLUSIONS The non-specific immunostimulatory effect of HET is suggested by this study to be effective in preventing the progression in IPDs and provided insights into novel strategy in the post-pneumococcal vaccine era.
Collapse
Affiliation(s)
- Tatsuya Shiga
- Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Kimiidera 811-1 Wakayama-shi, 641-8509, Wakayama, Japan
| | - Masamitsu Kono
- Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Kimiidera 811-1 Wakayama-shi, 641-8509, Wakayama, Japan
| | - Daichi Murakami
- Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Kimiidera 811-1 Wakayama-shi, 641-8509, Wakayama, Japan
| | - Hideki Sakatani
- Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Kimiidera 811-1 Wakayama-shi, 641-8509, Wakayama, Japan
| | - Keisuke Ogura
- Tsumura Kampo Research Laboratories, Kampo Research & Development Division, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, 300-1192, Ibaraki, Japan
| | - Muneki Hotomi
- Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Kimiidera 811-1 Wakayama-shi, 641-8509, Wakayama, Japan.
| |
Collapse
|
2
|
Yamamoto M. KAMPOmics: A framework for multidisciplinary and comprehensive research on Japanese traditional medicine. Gene X 2022; 831:146555. [PMID: 35569769 DOI: 10.1016/j.gene.2022.146555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 03/18/2022] [Accepted: 05/06/2022] [Indexed: 11/04/2022] Open
Abstract
Traditional Japanese medicines, known as "Kampo medicines", are pharmaceutical-grade multi-herbal treatments that are integrated within the modern medical system in Japan. Although basic and clinical research including placebo-controlled double-blind trials is attempting to clarify their effectiveness and mechanisms of action, such studies are seriously limited due to the multi-targeted, multi-component "long-tail" properties of Kampo medicines, which are fundamentally different from modern western therapeutics. However, recent progress in high-throughput analytical technology, coupled with an exponential increase in biomedical information on various levels from molecular biology to clinical "big" data, is enabling us to commence a multidisciplinary and comprehensive investigation of Kampo medicines based on multi-omics, bio-informatics, and systems biology. In addition to deriving an inclusive understanding of the benefits and mechanisms of Kampo medicines, "KAMPOmics" may lead to the development of new principles to control and treat diseases in a systems-oriented manner. Furthermore, elucidation of "sho" and "mibyo" - classical concepts of Kampo, which loosely approximate to the notions of "precise medicine" and "pre-symptomatic aberration", respectively - may contribute to the development of patient-oriented medicine, an area attracting enormous growth and interest in contemporary medicine.
Collapse
Affiliation(s)
- Masahiro Yamamoto
- Tsumura Research Laboratories, Tsumura & Co., Yoshiwara 3586, Ami, Inashiki, Ibaraki 300-1192, Japan.
| |
Collapse
|
3
|
Takayama S, Kikuchi A, Makino T, Kainuma M, Namiki T, Ito T. Basic pharmacological mechanisms and clinical evidence of the efficacy of hochuekkito against infectious diseases and its potential for use against COVID‐19. TRADITIONAL & KAMPO MEDICINE 2020. [PMCID: PMC7753421 DOI: 10.1002/tkm2.1264] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Background Hochuekkito extract (HET) has multiple effects through the digestive and immune systems, including for acute viral infection and chronic inflammation. We review basic pharmacological and clinical researches of HET and discuss the effects of HET against the pandemic COVID‐19. Methods We reviewed pharmacological studies from 1996 to 30 April 2020 that used experimental animals orally treated with HET and randomized controlled trials (RCTs) from 2000 to 30 April 2020. Results Altogether, 64 pharmacological studies reported immuno‐stimulatory effects against infection and cancer, immuno‐modulative effects against allergy and some inflammatory diseases, and ameliorating effects against exhaustion and frailty. Nine RCTs showed improvement of pulmonary Mycobacterium avium complex disease on chest X‐ray; improved systemic inflammation, nutrition, and quality of life of patients with chronic obstructive pulmonary disease and a decrease in the number getting common cold and exacerbations; reduction of soluble interleukin‐2 receptor and the serum cortisol concentration of postoperative patients; a reduction of the incidence of inflammatory complications and C‐reactive protein elevation after cerebrovascular disease; a reduction of the volume of steroid and tacrolimus during the treatment of atopic dermatitis; a healing effect for intractable chronic wounds; improvement of the physical status of elderly weak patients; and improvement of the fatigue level of cancer patients. Conclusion CODIV‐19 is characterized by high risk for the aged and people with other disease complications, cytokine hyperactivity in the severe stage, and sequelae in the recovery stage. Considering the immune‐stimulative/modulative effects of HET on inflammatory conditions and against exhaustion and frailty, it may be useful for prevention, treatment, and recovery from COVID‐19.
Collapse
Affiliation(s)
- Shin Takayama
- Department of Kampo Medicine Tohoku University Hospital Sendai Japan
- Department of Education and Support for Regional Medicine Tohoku University Hospital Sendai Japan
- Department of Kampo and Integrative Medicine Tohoku University Graduate School of Medicine Sendai Japan
| | - Akiko Kikuchi
- Department of Kampo Medicine Tohoku University Hospital Sendai Japan
- Department of Education and Support for Regional Medicine Tohoku University Hospital Sendai Japan
- Department of Kampo and Integrative Medicine Tohoku University Graduate School of Medicine Sendai Japan
| | - Toshiaki Makino
- Department of Pharmacognosy Graduate School of Pharmaceutical Sciences, Nagoya City University Nagoya Japan
| | - Mosaburo Kainuma
- Community Medicine Education Unit Graduate School of Medical Science, Kyushu University Fukuoka Japan
| | - Takao Namiki
- Department of Japanese‐Oriental (Kampo) Medicine Graduate School of Medicine, Chiba University Chiba Japan
| | | |
Collapse
|
4
|
Yin E, Uchiyama M, Niimi M. Induction of Regulatory CD4 + Cells and Prolongation of Fully Major Histocompatibility Complex Mismatched Murine Cardiac Allograft by Shigyakusan. Transplant Proc 2018; 50:274-282. [PMID: 29407322 DOI: 10.1016/j.transproceed.2017.12.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2017] [Revised: 11/19/2017] [Accepted: 12/12/2017] [Indexed: 11/16/2022]
Abstract
Shigyakusan (also known as Tsumura Japan [TJ]-35) is composed of peony, bitter orange, licorice, and Bupleuri radix is used for cholecystitis and gastritis as an anti-inflammatory agent. We investigated the effect of TJ-35 on alloimmune response in a murine heart transplantation model. CBA mice that underwent transplantation of a C57BL/6 (B6) heart were assigned to four groups: no treatment, TJ-35-exposed, each component-exposed, or each component missing-exposed. The four groups above each received oral administration of TJ-35, each component, or TJ-35 with each component missing from the day of transplantation until 7 days, respectively. Untreated CBA recipients rejected B6 cardiac grafts acutely (median survival time [MST], 7 days). TJ-35-exposed CBA recipients had significantly prolonged B6 allograft survival (MST, 20.5 days). However, MSTs of CBA recipients that had been administered each component and TJ-35 with each component missing did not reach that of TJ-35-exposed recipients. Adoptive transfer of CD4+ splenocytes from TJ-35-exposed primary allograft recipients resulted in significant prolonged allograft survival in naïve secondary recipients (MST, 63 days). Flow cytometry studies showed that the percentage of CD4+CD25+Foxp3+ cell population was increased in TJ-35-exposed CBA recipients. In conclusion, TJ-35-induced prolongation of fully allogeneic cardiac allografts and may generate regulatory CD4+CD25+Foxp3+ cells in our model. The effect seemed to require all components of TJ-35.
Collapse
Affiliation(s)
- E Yin
- Department of Surgery, Teikyo University, Tokyo, Japan; Department of Cardiovascular Surgery, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, China
| | - M Uchiyama
- Department of Surgery, Teikyo University, Tokyo, Japan.
| | - M Niimi
- Department of Surgery, Teikyo University, Tokyo, Japan
| |
Collapse
|
5
|
He M, Chen W, Wang M, Wu Y, Zeng J, Zhang Z, Shen S, Jiang J. Simultaneous determination of multiple bioactive components of Bu-zhong-yi-qi-tang in rat tissues by LC-MS/MS: Application to a tissue distribution study. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1044-1045:177-184. [PMID: 28113140 DOI: 10.1016/j.jchromb.2017.01.023] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 12/13/2016] [Accepted: 01/17/2017] [Indexed: 02/08/2023]
Abstract
A liquid chromatography coupled with electrospray ionization mass spectrometry method was developed and validated for simultaneous determination of seven bioactive constituents including astragaloside IV, calycosin, glycyrrhizic acid, enoxolone, saikosaponin D, ferulic acid and hesperiden in rats' various tissues using diclofenac as the internal standard (IS). Biological samples were pretreated by protein precipitation with acetonitrile. The chromatographic separation was carried out on a C18 column with a gradient mobile phase consisting of acetonitrile and water (containing 0.1% formic acid and 4mM ammonium acetate). All analytes and IS were quantitated through electrospray ionization in negative ion multiple reaction monitoring mode. The mass transitions were as follows: m/z 829.7→783.3 for astragaloside IV, m/z 283.3→267.7 for calycosin, m/z 821.6→350.0 for glycyrrhizic acid, m/z 469.9→425.2 for enoxolone, m/z 825.7→779.6 for saikosaponin D, m/z 192.5→133.9 for ferulic acid, m/z 609.1→301.0 for hesperiden and m/z 293.6→249.9 for the IS, respectively. The lower limits of quantification for the seven analytes in different rat tissues were 0.2-20ng/mL. Bu-zhong-yi-qi-tang (Hochuekkito in Japan, Bojungikki-tang in Korea) is one of the most frequently prescribed traditional herbal formulas used in Korea, Japan, and China to treat gastrointestinal diseases, cancer and chronic fatigue syndrome. The validated method was successfully applied to a tissue distribution study of the seven components in rat tissue after oral administration of Bu-zhong-yi-qi-tang concentrated granule. The results of the tissue distribution study showed that the high concentration of seven components were mainly in the gastrointestinal tract.
Collapse
Affiliation(s)
- Min He
- Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
| | - Wenwen Chen
- Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
| | - Mengmeng Wang
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, China
| | - Yu Wu
- Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
| | - Jin Zeng
- Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
| | - Zhirong Zhang
- Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
| | - Shujiao Shen
- Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
| | - Jian Jiang
- Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China.
| |
Collapse
|
6
|
SATO TETSUO, KITA KAZUKO, SATO CHIHOMI, KANEDA ATSUSHI. Hochu-ekki-to (Bu-zhong-yi-qi-tang), a herbal medicine, enhances cisplatin-induced apoptosis in HeLa cells. Mol Med Rep 2015; 12:6215-20. [DOI: 10.3892/mmr.2015.4137] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 06/26/2015] [Indexed: 11/06/2022] Open
|
7
|
Enomoto Y, Hagiwara E, Komatsu S, Nishihira R, Baba T, Kitamura H, Sekine A, Nakazawa A, Ogura T. Pilot quasi-randomized controlled study of herbal medicine Hochuekkito as an adjunct to conventional treatment for progressed pulmonary Mycobacterium avium complex disease. PLoS One 2014; 9:e104411. [PMID: 25093868 PMCID: PMC4122490 DOI: 10.1371/journal.pone.0104411] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Accepted: 07/01/2014] [Indexed: 11/18/2022] Open
Abstract
Introduction Hochuekkito, a traditional herbal medicine, is occasionally prescribed in Japan to treat patients with a poor general condition. We aimed to examine whether this medicine was beneficial and tolerable for patients with progressed pulmonary Mycobacterium avium complex (MAC) disease. Methods This pilot open-label quasi-randomized controlled trial enrolled 18 patients with progressed pulmonary MAC disease who had initiated antimycobacterial treatment over one year ago but were persistently culture-positive or intolerant. All patients continued their baseline treatment regimens with (n = 9) or without (n = 9) oral Hochuekkito for 24 weeks. Results Baseline characteristics were generally similar between the groups. Most patients were elderly (median age 70 years), female, had a low body mass index (<20 kg/m2), and a long-term disease duration (median approximately 8 years). After the 24-week treatment period, no patient achieved sputum conversion. Although the number of colonies in sputum tended to increase in the control group, it generally remained stable in the Hochuekkito group. Radiological disease control was frequently observed in the Hochuekkito group than the control group (8/9 vs. 3/9; p = 0.05). Patients in the Hochuekkito group tended to experience increase in body weight and serum albumin level compared with those in the control group (median body weight change: +0.4 kg vs. −0.8 kg; median albumin change: +0.2 g/dl vs. ±0.0 g/dl). No severe adverse events occurred. Conclusions Hochuekkito could be an effective, feasible adjunct to conventional therapy for patients with progressed pulmonary MAC disease. Future study is needed to explore this possibility. Trial Registration UMIN Clinical Trials Registry UMIN000009920
Collapse
Affiliation(s)
- Yasunori Enomoto
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
- * E-mail:
| | - Eri Hagiwara
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Shigeru Komatsu
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Ryuichi Nishihira
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Tomohisa Baba
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Hideya Kitamura
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Akimasa Sekine
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Atsuhito Nakazawa
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Takashi Ogura
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| |
Collapse
|
8
|
Fukuchi M, Sakurai S, Kogure T, Naitoh H, Kuwano H. Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated with Hochuekkito, a Kampo Medicine, following Steroid Treatment. Case Rep Gastroenterol 2014; 8:193-8. [PMID: 24987323 PMCID: PMC4067706 DOI: 10.1159/000363536] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
We report a case of immunoglobulin G4 (IgG4)-related retroperitoneal fibrosis (RF) with complete remission and no relapses after therapy with steroids and Hochuekkito, a Kampo (i.e. traditional Japanese herbal) medicine. A 62-year-old Japanese man was admitted to our hospital for treatment of a retroperitoneal mass detected by computed tomography. The mass had a maximum diameter of 11.0 cm; it involved the left ureter and was associated with left hydronephrosis. After inserting a ureteral stent, we performed a biopsy by laparotomy. Histopathology revealed IgG4-related RF. The lesion disappeared after 7 months of steroid therapy. We subsequently used Hochuekkito as an alternative maintenance treatment because of steroid-related complications. The patient has not relapsed in the 3 years since starting the medication. To the best of our knowledge, this is the first case of IgG4-related RF treated with Hochuekkito as a maintenance treatment.
Collapse
Affiliation(s)
- Minoru Fukuchi
- Department of Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Shinji Sakurai
- Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Toshiaki Kogure
- Department of Japanese Oriental Medicine, Gunma Chuo Hospital, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Hiroshi Naitoh
- Department of Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Hiroyuki Kuwano
- Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan
| |
Collapse
|